Humacyte
HUMA
75 hedge funds and large institutions have $42.2M invested in Humacyte in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 7 closing their positions.
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
13% more capital invested
Capital invested by funds: $37.4M → $42.2M (+$4.8M)
9% more funds holding
Funds holding: 69 → 75 (+6)
2.57% more ownership
Funds ownership: 11.67% → 14.24% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
80% less call options, than puts
Call options by funds: $33K | Put options by funds: $167K
Top Buyers
| 1 |
BlackRock
New York
|
+$1.81M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
+$1.62M |
| 3 |
LM
Luminus Management
Houston,
Texas
|
+$1.44M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.36M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$1.35M |
Top Sellers
| 1 |
IW
Imprint Wealth
Mount Pleasant,
South Carolina
|
-$582K |
| 2 |
SG Americas Securities
New York
|
-$92K |
| 3 |
Millennium Management
New York
|
-$86K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$83.7K |
| 5 |
Jane Street
New York
|
-$67.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
SG Americas Securities
New York
| – | -$92K | -29,921 | Closed |
|
|
77
Millennium Management
New York
| – | -$86K | -27,875 | Closed |
|
|
RJA
78
Raymond James & Associates
St Petersburg,
Florida
| – | -$60K | -19,411 | Closed |
|
|
YIH
79
Y-Intercept (HK)
Hong Kong
| – | -$45K | -14,565 | Closed |
|
80
Kovitz Investment Group Partners
Chicago,
Illinois
| – | -$35K | -11,250 | Closed |
|
|
TWA
81
TCI Wealth Advisors
Tucson,
Arizona
| – | -$4.81K | -1,557 | Closed |
|
|
EI
82
Ellevest Inc
New York
| – | -$1.9K | -616 | Closed |
|
HUMA Hedge Fund Activity: Q2 2023 in Review
75 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q2 2023, worth a combined $42.2M — up 13% from $37.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new HUMA positions and 7 closed out — a net gain of 6 holders — while 34 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $1.81M. The largest seller was Imprint Wealth, cutting an estimated $582K.
- 75 institutional investors held Humacyte (HUMA) as of Q2 2023, up from 69 in Q1 2023.
- Funds reported $42.2M of Humacyte stock for Q2 2023, up 13% quarter-over-quarter.
- 13 funds opened new Humacyte positions in Q2 2023 and 7 closed out, a net change of +6 holders.
- The largest Humacyte buyer in Q2 2023 was BlackRock, an estimated $1.81M added.
- The largest Humacyte seller in Q2 2023 was Imprint Wealth, an estimated $582K sold.
Based on aggregated 13F filings for Q2 2023.